Revolutionary eye drops could prevent blindness in diabetes patients

diabetic retinopathy pr
23 May 2017 13:47:22.283

PA 113/17

Medical research is offering hope to the hundreds of thousands of diabetes patients who endure the discomfort of monthly injections into the eye to protect them from the risk of blindness.

A study being led by Professor David Bates at the University of Nottingham is investigating whether simple eye drops could be used instead to treat patients for the condition diabetic retinopathy.

If successful, the eye drops could be available to diabetic patients on clinical trials within the next three to five years.

Click here for full story

The research has been made possible thanks to a £60,000 grant from Nottinghamshire Freemasons and £37,000 from the National Eye Research Centre.

Professor David Bates in the University’s School of Medicine said: “We are extremely grateful for the grant we have received from the Freemasons and National Eye Research Centre. Without their support, this project would not have been possible and we would not be able to find out whether drugs that are already being developed for other eye diseases could be also be used in diabetic retinopathy.

“Diabetes is the leading cause of preventable sight loss in the working population in the UK. The impact of this research means that in the future diabetic patients could be offered a better, more effective way of preventing them from losing their sight.

“The current treatment for diabetic retinopathy is very unpleasant for the patient but also costly and time-consuming because the injection can only be performed at eye clinics by specialist doctors and nurses.

“Eye drops that patients could administer themselves would reduce both their discomfort and the financial burden which the current treatment places on the NHS.”

Rapid decline in vision

Around 1.2 million people are believed to suffer from diabetic retinopathy in the UK, with around 750,000 of those currently experiencing some form of visual impairment. The Royal National Institute for the Blind (RNIB) estimates that the total economic cost of sight loss including healthcare, social care and loss of employment, could be as high as £28bn per year. Globally, the condition affects in the region of 93 million people.

Diabetic retinopathy is a complication of diabetes caused by high blood sugar levels. Over time it can weaken and damage the small blood vessels within the retina which can cause haemorrhages, leaky blood vessels and swelling on the retina. This starves the retina of oxygen, causing abnormal blood vessels to grow. If left untreated over time it can affect vision and lead to blindness.

In more serious cases, the leaking blood vessels behind the eye can lead to the condition diabetic macular oedema in which fluid builds up in the macula, the part of the eye which provides us with our central vision. The condition of patients with diabetic macular oedema can decline very quickly and can lead to rapid visual impairment and blindness.

In the human body, a protein called VEGF (vascular endothelial growth factor) is responsible for the normal formation and growth of blood vessels. But in diabetic patients a type of VEGF is produced which causes the faulty blood vessels to grow and leak fluid into the eye.

Preventing sight loss

Current treatments target all forms of VEGF which prevent the growth of the faulty blood vessels but also stops the re-growth of normal blood vessels to help the eye recover from the effects of the high blood sugar levels.

Professor Bates and his team are investigating whether work aimed at developing eye drops for the condition Age-related Macular Degeneration (AMD) could also work to prevent sight loss in diabetic patients.

Studies have shown that in models of AMD, drugs can be used to target the protein SRPK1 which can switch off the detrimental form of VEGF and enable the good form of VEGF to promote normal blood vessel growth and protect the endothelial cells which line the interior surface of the blood vessels.

The current drug, which is used to switch off VEGF completely, is a large molecule, meaning it can only be administered by injection. However, the drugs which target SRPK1 are much smaller meaning that they could be given in the form of eye drops.

The eye drops for AMD are likely to be in clinical trials within two to three years, and could be followed shortly with a multi-centre year-long phase 3 clinical trial for diabetes patients.

Philip Marshall from Nottinghamshire Freemasons said: “We’re very pleased to be able to support this hugely important project, which offers hope for preventing blindness in millions of diabetic patients in this country and around the world.”

Mike Daw, Chief Executive of National Eye Research Centre said: “National Eye Research Centre is immensely proud to have been able to fund this research into finding improved treatments for this leading cause of preventable blindness in the UK.”

— Ends —

Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email or see the Globelynx website for how to register for this service.

For up to the minute media alerts, follow us on Twitter

Notes to editors: The University of Nottingham has 43,000 students and is ‘the nearest Britain has to a truly global university, with a “distinct” approach to internationalisation, which rests on those full-scale campuses in China and Malaysia, as well as a large presence in its home city.’ (Times Good University Guide 2016). It is also one of the most popular universities in the UK among graduate employers and was named University of the Year for Graduate Employment in the 2017 The Times and The Sunday Times Good University Guide. It is ranked in the world’s top 75 by the QS World University Rankings 2015/16, and 8th in the UK for research power according to the Research Excellence Framework 2014. It has been voted the world’s greenest campus for four years running, according to Greenmetrics Ranking of World Universities.

Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…


Story credits

More information is available from Professor David Bates in the School of Medicine, University of Nottingham on +44 (0)115 823 1135,

Emma Thorne Emma Thorne - Media Relations Manager

Email: Phone: +44 (0)115 951 5793 Location: University Park

Additional resources

No additional resources for this article

Related articles

From eyedrops to potential leukaemia treatment

Published Date
Wednesday 19th December 2018

Medical discovery first step on path to new painkillers

Published Date
Wednesday 1st October 2014

Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798